Completed PHASE3 INTERVENTIONAL NCT00046137

Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis

Sponsor: Eli Lilly and Company

Interventions placebo raloxifene teriparatide

Updated 6 times since 2017 Last updated: Jul 19, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Osteoporosis, Postmenopausal and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altamonte Springs, United States , Anaheim, United States , Baltimore, United States , Cedar Rapids, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Duncansville, United States , Hagerstown, United States , Oakland, United States and 3 more locations